RIGL Financial Facts
Interest income: 110KTotal costs and expenses: 26.5M
See Full Income Statement
Other long-term liabilities: 8K
Long-term portion of deferred rent: 994K
See Full Balance Sheet
Rigel Pharmaceuticals, Inc. (RIGL) Earnings
|
Expand Research on RIGL
| Next EPS Date | 8/4/26 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | 0.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +6.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/4/26  |
Q226 | N/A | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 5/5/26 | Q126 | $0.44 | $0.00 | +$0.44 | $58.8M | N/A | N/A |  | | Details | |
| 3/3/26 | Q425 | $13.54 | $0.00 | +$13.54 | $69.8M | N/A | N/A | | | Details | |
| 11/4/25 |
Q325 | N/A | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 11/4/25 | Q325 | $1.46 | $0.00 | +$1.46 | $69.46M | N/A | N/A | | | Details | |
| 5/6/25 | Q125 | $0.63 | $0.00 | +$0.63 | $53.33M | N/A | N/A | | | Details | |
| 3/4/25 | Q424 | $0.80 | $0.00 | +$0.80 | $57.6M | N/A | N/A | | | Details | |
| 8/6/24 | Q224 | -$0.06 | -$0.02 | -$0.04 | $36.84M | $33.7M | N/A | | | Details |
